@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix hgnc: . @prefix proteinModification: . @prefix psimod: . @prefix go: . @prefix Protein: . @prefix geneProductOf: . @prefix hasPart: . @prefix ProteinComplex: . @prefix hasAgent: . @prefix mesh: . @prefix occursIn: . @prefix hasAnnotation: . @prefix species: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 belv:variantOf hgnc:6155; a proteinModification:, psimod:00696 . sub:_2 hasAgent: sub:_3; a go:0003674 . sub:_3 hasPart: sub:_4, sub:_5; a ProteinComplex: . sub:_4 geneProductOf: hgnc:6149; a Protein: . sub:_5 geneProductOf: hgnc:6155; a Protein: . sub:_6 occursIn: mesh:D001769, mesh:D002462, mesh:D009131, mesh:D009504, species:10090; hasAnnotation: sub:_7; rdf:object sub:_2; rdf:predicate belv:directlyIncreases; rdf:subject sub:_1; a rdf:Statement . sub:_7 dct:subject "TextLocation"; rdf:value "Review" . sub:assertion rdfs:label "p(HGNC:ITGB2,pmod(P)) => act(complex(p(HGNC:ITGAM),p(HGNC:ITGB2)))" . } sub:provenance { beldoc: dce:description "Approximately 2000 hand curated statements drawn from 57 PubMeds."; dce:rights "Copyright (c) 2011-2012, Selventa. All Rights Reserved."; dce:title "BEL Framework Small Corpus Document"; dct:license "Creative Commons Attribution-Non-Commercial-ShareAlike 3.0 Unported License"; pav:authoredBy sub:_9; pav:version "1.6" . sub:_8 prov:value """Preformed Mac-1 is stored in granules in neutrophils and can be rapidly mobilized to the neutrophil surface after exposure to degranulation stimuli such as the bacterial peptide fMLP or to cytokines (Altieri and Edgington, 1988). However, it is not yet competent for ligand binding. The ligand binding site lies on an extracellular region of the α subunit called the I domain, that is inaccessible to potential ligands unless integrins are activated. Integrin activation involves a conformational change such that the I domain is exposed (Oxvig et al., 1999). This change may be induced by phosphorylation of the cytoplasmic tail of the β subunit (Buyon et al., 1997), possibly through a pathway involving the small GTP-binding protein Rho, but this is still unclear."""; prov:wasQuotedFrom pubmed:12891700 . sub:_9 rdfs:comment "support@belframework.org"; rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:12891700; prov:wasDerivedFrom beldoc:, sub:_8 . } sub:pubinfo { this: dct:created "2014-07-03T14:29:34.936+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }